STO: CALTX Statistics

Total Valuation

Calliditas Therapeutics AB has a market cap or net worth of SEK 11.24 billion. The enterprise value is 11.45 billion.

Market Cap	11.24B
Enterprise Value	11.45B

Important Dates

The last earnings date was Monday, November 11, 2024.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

Calliditas Therapeutics AB has 54.03 million shares outstanding. The number of shares has increased by 0.40% in one year.

Current Share Class	n/a
Shares Outstanding	54.03M
Shares Change (YoY)	+0.40%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	0.17%
Owned by Institutions (%)	23.72%
Float	2.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	16.38
PS Ratio	6.97
PB Ratio	105.20
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-23.84
EV / Sales	7.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-44.43

Financial Position

The company has a current ratio of 2.69, with a Debt / Equity ratio of 9.44.

Current Ratio	2.69
Quick Ratio	2.37
Debt / Equity	9.44
Debt / EBITDA	n/a
Debt / FCF	-3.91
Interest Coverage	-3.55

Financial Efficiency

Return on equity (ROE) is -157.20% and return on invested capital (ROIC) is -19.31%.

Return on Equity (ROE)	-157.20%
Return on Assets (ROA)	-13.41%
Return on Capital (ROIC)	-19.31%
Revenue Per Employee	7.21M
Profits Per Employee	-2.16M
Employee Count	217
Asset Turnover	0.93
Inventory Turnover	3.62

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +110.74% in the last 52 weeks. The beta is 1.46, so Calliditas Therapeutics AB's price volatility has been higher than the market average.

Beta (5Y)	1.46
52-Week Price Change	+110.74%
50-Day Moving Average	206.68
200-Day Moving Average	158.28
Relative Strength Index (RSI)	64.81
Average Volume (20 Days)	25,665

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Calliditas Therapeutics AB had revenue of SEK 1.60 billion and -480.36 million in losses. Loss per share was -8.95.

Revenue	1.60B
Gross Profit	1.50B
Operating Income	-370.67M
Pretax Income	-468.32M
Net Income	-480.36M
EBITDA	-365.37M
EBIT	-370.67M
Loss Per Share	-8.95

Full Income Statement

Balance Sheet

The company has 797.28 million in cash and 1.01 billion in debt, giving a net cash position of -210.99 million or -3.90 per share.

Cash & Cash Equivalents	797.28M
Total Debt	1.01B
Net Cash	-210.99M
Net Cash Per Share	-3.90
Equity (Book Value)	106.79M
Book Value Per Share	1.98
Working Capital	724.69M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -244.93 million and capital expenditures -12.79 million, giving a free cash flow of -257.72 million.

Operating Cash Flow	-244.93M
Capital Expenditures	-12.79M
Free Cash Flow	-257.72M
FCF Per Share	-4.77

Full Cash Flow Statement

Margins

Gross margin is 93.46%, with operating and profit margins of -23.15% and -30.00%.

Gross Margin	93.46%
Operating Margin	-23.15%
Pretax Margin	-29.24%
Profit Margin	-30.00%
EBITDA Margin	-22.82%
EBIT Margin	-23.15%
FCF Margin	-16.09%

Dividends & Yields

Calliditas Therapeutics AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.40%
Shareholder Yield	-0.40%
Earnings Yield	-4.30%
FCF Yield	-2.29%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a